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Reply to the Editor:
We thank Dr Li and colleagues for their
important comments to our article and ap-
preciate their remarks. In particular, their
results in patients during the postoperative
period concerning determinants and impli-
cations of oxygen consumption (VO2), a
patient group that was not included by us,
are essential.1
In addition, their work presents the im-
portant conclusion that also other predictive
equations published by LaFarge-Miettinen,
Lundell and associates2, Wessel and col-
leagues,3 and Lindahl4 do not accurately es-
timate VO2. Of course we should have cited
their article.1,5
Our study was especially designed to
assess the importance of measured VO2 in
the preoperative diagnostic hemodynamic
evaluation during cardiac catheterization.
Our results emphasize that both the Krovetz-
Goldbloom formula,6 which was used so far
in our institution, and the most commonly
used formula published by LaFarge and
Miettinen2 are not feasible in all patients to
assume VO2 to calculate cardiac output by
using the Fick principle.
In contrast to the studies by Li and
associates,1,5 VO2 was measured with the
standard commercial metabolic monitor
Deltatrac II (Datex-Engström, Helsinki,
Finland). This system is an open-air system
equipped with a fast differential paramag-
netic oxygen sensor to measure a differen-
tial signal between inspired and expired
gases and a gas dilution system to measure
flow.7,8 In contrast to the mass spectrome-
ter method used by Li and associates, in our
design no special adaptation in ventilated
patients was necessary. After exclusion of
any relevant air leak, the Deltatrac II device
is easy to handle and allows a feasible and
reliable method to measure VO2.
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Anesthetic preconditioning as the
alternative to ischemic
preconditioning
To the Editor:
We read with interest the article by Canyon
and Dobson1 presenting a combination of
the adenosine A1 agonist 2-chloro-N6-
cyclopentyladenosine (CCPA) and lidocaine
as a possibly useful alternative to ischemic
preconditioning in the clinical setting. As
Canyon and Dobson1 state, “A goal for
more than 2 decades has been to develop a
pharmacologic mimetic of IPC [ischemic
preconditioning] to protect the heart during
acute regional ischemia.” Canyon and
Dobson1 unfortunately did not mention that
volatile anesthetics are potent triggers of
preconditioning, especially in the perioper-
ative setting. Volatile anesthetic-induced
preconditioning leads to a profound infarct
size reduction, as effectively as does isch-
emic preconditioning,2 and follows a dose-
response relationship.3 Desflurane, enflu-
rane, halothane, isoflurane, and sevoflurane
induce anesthetic preconditioning.4,5 Apart
from these experimental data, there is clear
evidence for preconditioning by volatile
anesthetics in human beings. Recent clini-
cal studies indicate that volatile anesthetics
confer cardioprotective effects in high-risk
patients undergoing coronary surgery.6-8
Sevoflurane-induced preconditioning has
been seen to preserve myocardial function
and decrease troponin I levels after cardio-
pulmonary bypass7 and even to reduce the
incidence of late adverse cardiac events
during the first year after surgery.8 Canyon
and Dobson1 emphasized that coadminis-
tration of lidocaine and CCPA was able to
prevent life-threatening arrhythmias during
ischemia and reperfusion. Again, volatile
anesthetics show similar qualities: anes-
thetic preconditioning significantly reduces
arrhythmias after ischemic periods.9 Stim-
ulation of adenosine A1 receptors, among
other membrane receptors, is part of the
signal transduction pathway of anesthetic
preconditioning.10 Therefore, it is unlikely
that the administration of a selective aden-
osine A1 agonist in addition to a volatile
anesthetic would further enhance cardio-
protection. Canyon and Dobson1 suggest
intracoronary administration of CCPA and
lidocaine for percutaneous interventions,
off-pump and on-pump heart surgery, and
perioperative applications. Apart from per-
cutaneous coronary interventions, patients
are anesthetized throughout these proce-
dures. An inhalational anesthetic regimen
would therefore appear to be the method of
choice for patients at risk for perioperative
ischemia because it would confer profound
cardioprotection without the need for po-
tentially deleterious additional intracoro-
nary medication. Patients undergoing per-
cutaneous coronary interventions might
benefit from emulsified volatile anesthet-
ics, administered intravenously at subanes-
thetic doses, in the near future.11
In conclusion, there is a large body of
evidence demonstrating that volatile anes-
thetics effectively induce cardioprotection,
to the benefit of high-risk cardiac patients.
Therefore, the need for adjuvant CCPA or
lidocaine administered additionally to a pa-
tient already being protected by volatile
anesthetics is questionable and remains to
be proven.
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